CX-4945 in Viral Community Acquired Pneumonia

NCT ID: NCT06202521

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-03-20
• Study Completion Date: 2025-04-22

Brief Summary

This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated pneumonia. The subjects will be recruited into two domains, including SARS-CoV-2 and influenza virus domains. The study will compare the efficacy of Standard of Care (SOC) combined with CX-4945 against SOC paired with a placebo, utilizing a 1:1 allocation ratio in each domain.

Detailed Description

Domain I: SARS-CoV-2 domain

• Arm 1: CX-4945 (400 mg BID for 5 days) +SOC
• Arm 2: Placebo + SOC

Domain II: Influenza virus domain

• Arm 3: CX-4945 (400 mg BID for 5 days) +SOC
• Arm 4: Placebo + SOC

Screening visit will collect health information and perform protocol specified tests to determine patients' eligibility. After screening visit, eligible subjects who fulfill all selection criteria for enrollment will be randomized into each of the arms. The CX-4945 will be administered at 400 mg BID for 5 days. Subjects will be followed up until Day 29.

Conditions

Community-acquired Pneumonia; SARS-CoV-2 -Associated Pneumonia; Influenza With Pneumonia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SARS-CoV-2 domain: CX-4945 (400 mg BID for 5 days) +SOC

Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.

Group Type: EXPERIMENTAL

CX-4945 (SARS-CoV-2 domain)

Intervention Type: DRUG

CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

SARS-CoV-2 domain: Placebo + SOC

Notes: The SOC within the SARS-CoV-2 domain is defined as the medications in use at each respective site for the treatment of CAP related to SARS-CoV-2 infection.

Group Type: PLACEBO_COMPARATOR

Placebo (SARS-CoV-2 domain)

Intervention Type: DRUG

The dosage and frequency is the same as active drug.

Influenza virus domain: CX-4945 (400 mg BID for 5 days) +SOC

Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.

Group Type: EXPERIMENTAL

CX-4945 (Influenza virus domain)

Intervention Type: DRUG

CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

Influenza virus domain: Placebo + SOC

Notes: The SOC within the influenza virus domain is defined as the medications in use at each respective site for the treatment of CAP related to influenza virus infection.

Group Type: PLACEBO_COMPARATOR

Placebo (Influenza virus domain)

Intervention Type: DRUG

The dosage and frequency is the same as active drug.

Interventions

CX-4945 (SARS-CoV-2 domain)

CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

Intervention Type: DRUG

Placebo (SARS-CoV-2 domain)

The dosage and frequency is the same as active drug.

Intervention Type: DRUG

CX-4945 (Influenza virus domain)

CX-4945 will be administered at 400 mg BID for up to 5 days (Day 1 to Day 5) in addition to SOC.

Intervention Type: DRUG

Placebo (Influenza virus domain)

The dosage and frequency is the same as active drug.

Intervention Type: DRUG

Other Intervention Names

Silmitasertib; Silmitasertib

Eligibility Criteria

Inclusion Criteria

1. Not currently hospitalized

2. Males or females aged ≥ 18 years at the time of signing the informed consent form (ICF)

3. Patients diagnosed with viral pneumonia, as determined by the investigator, who exhibit any of the subsequent criteria: presence of respiratory symptoms or fever (ear temperature ≥ 38 °C, base of the tongue temperature ≥ 37.5 °C, or axillary temperature ≥ 37 °C)

4. With a pneumonia severity index (PSI) of risk class II or III

5. Oxygen saturation measured by pulse oximetry (SpO2) ≥ 94% on room air at sea level

6. Positive test for SARS-CoV-2 or influenza virus infection, confirmed by rapid diagnostic test (excluding cases where both SARS-CoV-2 and influenza virus are positive)

7. Confirmed lower respiratory tract infection by X-ray

8. At screening, subjects capable of childbearing must provide a negative serum or urine pregnancy test. These subjects must also commit to adhering to the study-specified contraceptive methods throughout the study duration

Notes: Acceptable contraceptive methods include:

• Established use of oral, injected or implanted hormonal methods of contraception
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps)

9. The participant (or legal representative) agrees and is able to adhere to study protocol-stated requirements, instructions, and restrictions in the investigator's judgement. Furthermore, the participant is capable of understanding and has signed the IRB-approved Informed Consent Form (ICF)

10. With at least two of the risk factors listed below: Age ≥ 50 years-old; cancer and a life expectancy of ≥ 6 months; HIV infection; immunocompromised patient; congestive heart failure (CHF), or coronary artery disease (CAD), or cardiomyopathies; chronic kidney disease (CKD); chronic liver disease; chronic lung disease; diabetes mellitus (DM); body mass index (BMI) > 25 kg/m2; asthma; cerebrovascular disease; cystic fibrosis; dementia; or current and former smoker

Exclusion Criteria

1. Subject received investigational treatment within 30 days prior to the study, or concurrent use of another investigational drug

2. Subject has a history of severe renal disease (required phosphate binders or dialysis)

3. Subject has chronic diarrhea, characterized by three or more loose stools daily for a minimum of four weeks

4. High likelihood of mortality within the next 48 hours, as assessed by the investigator

5. Subject showing signs of respiratory failure and mechanical ventilation is required

6. Subject with liver cirrhosis

7. Subject with hepatitis B and/or hepatitis C disease, unless the subject has an aspartate aminotransferase (AST) level ranging from 8 to 31 U/L and an alanine aminotransferase (ALT) level from 0 to 41 U/L

8. Known active tuberculosis

9. Current documented bacterial infection

10. Subject has a documented anaphylactic reaction, regardless of cause

11. Subject who has taken an antiviral agent against respiratory viral infection for a continuous duration of more than 24 hours before screening

12. Subject is with active gastrointestinal diseases including gastritis, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis

13. Subjects received warfarin within 14 days prior to screening or intend to during the screening or treatment phase

14. History of allergic reactions to any of the ingredients or components used in the manufacture of CX-4945

15. Women who are pregnant or breastfeeding, or planning pregnancy during the study

Note: Men and women of reproductive potential must commit to effective contraception methods or abstinence during the study. Any resulting pregnancies or suspected pregnancies must be reported to the treating physician immediately.

16. ALT or AST levels > 5 times upper limit of normal (ULN)

17. eGFR <30 mL/min/1.73m2 (calculated by the MDRD formula)

18. Absolute neutrophil count (ANC) <1000/μL

19. Have received treatment with a SARS-CoV-2 specific monoclonal antibody

20. Have received convalescent COVID-19 plasma treatment

21. Concurrent use of baricitinib

22. Any physical findings or illness history that may compromise study results or increase patient risk, as determined by the investigator

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Senhwa Biosciences, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jason Huang, M.D.

Role: STUDY_CHAIR

Senhwa Biosciences

Locations

Kaohsiung Veterans General Hospital

Kaohsiung City, , Taiwan

Far Eastern Memorial Hospital

New Taipei City, , Taiwan

Taichung Veterans General Hospital

Taichung, , Taiwan

National Taiwan University Cancer Center, National Taiwan University Hospital

Taipei, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Tri-Service General Hospital

Taipei, , Taiwan

Taoyuan General Hospital, Ministry of Health and Welfare

Taoyuan District, , Taiwan

Countries

Taiwan

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CX-4945-011

Identifier Type: -

Identifier Source: org_study_id